Journal of Neuro-Oncology

, Volume 2, Issue 4, pp 325–330 | Cite as

Randomized trial of radiotherapy versus radiotherapy plus metronidazole for the treatment metastatic cancer to brain

A Southwest Oncology Group study
  • Harmon J Eyre
  • Joel D Ohlsen
  • Jess Frank
  • Albert F LoBuglio
  • Joseph D McCracken
  • T J Weatherall
  • C M Mansfield


One hundred sixteen eligible patients with metastatic cancer to the brain were randomized to receive either radiotherapy 3000 rad/ 10 fractions (treatment 1) or the same radiotherapy plus metronidazole 6 gm/m2 (treatment 2). One hundred eleven patients were either fully or partially evaluable. The response rates (CR + PR) and survival showed no significant differences between treatments. Treatment 1: CR + PR 24%, median survival 14 weeks, Treatment 2: CR + PR 27%, median survival 12 weeks. There were no differences observed in response rates based on primary tumor site, neurologic performance status, or extent of metastatic disease. Metronidazole therapy was associated with substantial nausea and vomiting but no neurotoxicity was observed. Oral metronidazole given every other day during radiation therapy provided no clinical benefit for patients with brain metastases compared to radiotherapy alone.


brain metastases radiotherapy 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Espana P, Chang P, Wiernik PH: Increased incidence of brain metastases in sarcoma patients. Cancer 45:377–380, 1980.Google Scholar
  2. 2.
    Mayer RJ, Berkowitz RS, Griffiths CT: Central nervous system involvement by ovarian carcinoma. A complication of prolonged survival with metastatic disease. Cancer 41: 776–783, 1978.Google Scholar
  3. 3.
    Nugent JL, Bunn PA, Jr, Mathews MJ et al.: CNS metastases in small cell bronchiogenic carcinoma. Increasing frequency and changing pattern with lengthening survival. Cancer 44:1885–1893, 1979.Google Scholar
  4. 4.
    Posner JB, Chernik NL: Intracranial metastases from systemic cancer. Adv Neurol 19:579–592, 1978.Google Scholar
  5. 5.
    Aronson SM, Garcia JH, Aronson BE: Metastatic neoplasms of the brain: Their frequency in relation to age. Cancer 17:558–563, 1964.Google Scholar
  6. 6.
    Zimm S, Wampler GL, Stablein D, Hazra T, Young HF: Intracerebral metastases in solid-tumor patients: Natural history and results of treatment. Cancer 48:384–394, 1981.Google Scholar
  7. 7.
    Posner JB: Management of central nervous system metastases. Semin Oncol 4:81–91, 1977.Google Scholar
  8. 8.
    Cairncross JG, Kim JH, Posner JB: Radiation therapy for brain metastases. Ann Neurol 7:529–541, 1980.Google Scholar
  9. 9.
    Deutsch M, Parsons JA, Mercado R, Jr: Radiotherapy for intracranial metastases. Cancer 34:1607–1661, 1974.Google Scholar
  10. 10.
    Marksbery WR, Books WH, Gupta GD, Young B: Treatment of patients with cerebral metastases. Arch Neurol 35:754–756, 1978.Google Scholar
  11. 11.
    Brogelt B, Gelber R, Kramer S et al.: The palliation of brain metastases: final results of the first two studies by the Radiation Therapy Oncology Group. Int J Radiation Oncology Biol Phys 6:1–9, 1980.Google Scholar
  12. 12.
    Kurtz JM, Gelber R, Brady LW, Carella RJ, Cooper JS: The palliation of brain metastases in a favorable patient population: A randomized clinical trial by the Radiation Therapy Oncology Group. Int J Radiation Oncology Biol Phys 7:891–895, 1981.Google Scholar
  13. 13.
    White KT, Fleming TR, Lows ER: Single metastases to the brain- Surgical treatment in 122 consecutive patients. Mayo Clin Proc 56:424–428, 1981.Google Scholar
  14. 14.
    Chapman JD, Reuvers AP, Borsa J et al.: Nitroheterocytic drugs as selective radiosensitizers of hypoxic mammalian cells. Cancer Chemother Rep 58:559–570, 1974.Google Scholar
  15. 15.
    Urtasun R, Band P, Chapman JD et al.: Radiation and high-dose metronidazole in supratentorial glioblastomas. New Engl J Med 294:1364–1367, 1976.Google Scholar
  16. 16.
    Kaplan EL, Meier P: Nonparametic estimation from incomplete observations. J Am Stat Assoc 53:457–481, 1958.Google Scholar
  17. 17.
    Gehan EA: A generalized Wilcoxin test for comparing arbitrarily singly-censored samples. Biometricha 52:203–223, 1965.Google Scholar
  18. 18.
    Mantel N: Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemotherapy Rep 50:163–170, 1966.Google Scholar
  19. 19.
    Phillips TL, Wasserman TH, Johnson RJ et al.: Final report on the United States phase I clinical trial of the hypoxic cell radiosensitize, misonidazole (Ro-70–0582; NSC #261037). Cancer 48:1697–1704, 1981.Google Scholar
  20. 20.
    Ang KK, VanderScheneren E, Notter G et al.: Split course multiple daily fractionated radiotherapy schedule combined with misonidazole for management of grade III and grade IV glioma. A pilot feasability study of the radiotherapy group of EORTC. Int J Radiation Oncology Biol Phys 8:1657–1664, 1982.Google Scholar
  21. 21.
    Madojewicz S, West CR, Park HC et al.: Phase II study-intra-arterial BCNU therapy for metastatic brain tumors. Cancer 47:653–657, 1981.Google Scholar
  22. 22.
    Salcman M, Samaros GM: Hyperthermia for brain tumors: Biophysical rational. Neurosurgery 9:327–335, 1981.Google Scholar
  23. 23.
    Neuwelt EA, Diehl JT, Vu LH et al.: Monitoring of methotrexate delivery in patients with malignant brain tumors after osmotic blood-brain barrier disruption. Ann Intern Med 94:449–454, 1981.Google Scholar

Copyright information

© Martinus Nijhoff Publishers 1984

Authors and Affiliations

  • Harmon J Eyre
    • 1
  • Joel D Ohlsen
    • 1
  • Jess Frank
    • 2
  • Albert F LoBuglio
    • 3
  • Joseph D McCracken
    • 4
  • T J Weatherall
    • 5
  • C M Mansfield
    • 6
  1. 1.University of Utah Medical CenterUSA
  2. 2.Southwest Oncology Group Biostatistical CenterUSA
  3. 3.University of Michigan Medical CenterUSA
  4. 4.Brook Army Medical CenterUSA
  5. 5.Tulane UniversityUSA
  6. 6.University of Kansas Medical CenterUSA

Personalised recommendations